July 6th, 2016. Sinotau USA Inc., a wholly owned subsidiary of Sinotau Pharmaceuticals Group, has signed an exclusive agreement with FluoroPharma Medical Inc., US company located in New Jersey. With this agreement, Sinotau will develop and commercialize FluoroPharma's patented cardiac imaging products CardioPET and BFPET in China and Canada.
These two agents address two different aspects of cardiovascular disease (CVD) with Positron Emission Tomography (PET) imaging. Both products are in Phase II studies showing very promising results.
FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels.